ACHCHealthcare · Medical Care FacilitiesThe 14 Wall Street analysts covering Acadia Healthcare Co., Inc. hold a median 12-month price target of $33 — +1.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 4 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Acadia Healthcare Co., Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (18): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ACHC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +1.2% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Sept 2026 | Leerink Partners | Maintains | Market Perform | $30 → $33 |
| 30 July 2026 | Barclays | Maintains | Equal-Weight | — |
| 30 July 2026 | Barclays | Maintains | Equal-Weight | $25 → $32 |
| 30 July 2026 | Guggenheim | Maintains | Buy | — |
| 30 July 2026 | Guggenheim | Maintains | Buy | $38 → $39 |
| 20 July 2026 | Guggenheim | Maintains | Buy | — |
| 20 July 2026 | Guggenheim | Maintains | Buy | $31 → $38 |
| 14 July 2026 | Keybanc | Maintains | Overweight | $30 → $40 |
| 14 July 2026 | Keybanc | Maintains | Overweight | — |
| 14 July 2026 | TD Cowen | Maintains | Buy | — |
| 14 July 2026 | TD Cowen | Maintains | Buy | $30 → $36 |
| 9 July 2026 | UBS | Maintains | Buy | $31 → $39 |
| 9 July 2026 | UBS | Maintains | Buy | — |
| 3 June 2026 | Jefferies | Upgrade | Buy | — |
| 4 May 2026 | Guggenheim | Maintains | Buy | — |
| 4 May 2026 | RBC Capital | Maintains | Outperform | — |
| 1 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 1 May 2026 | Cantor Fitzgerald | Maintains | Neutral | — |
| 28 Apr 2026 | TD Cowen | Maintains | Buy | — |
| 17 Apr 2026 | UBS | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ACHC appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Acadia Healthcare Co., Inc. returned +55.5% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 37% of US stocks
Cheaper than 72% of US stocks
Cheaper than 58% of US stocks
Cheaper than 37% of US stocks
Higher than 27% of US stocks
Higher than 8% of US stocks
Higher than 99% of US stocks
Higher than 64% of US stocks
Higher than 13% of US stocks
Higher than 24% of US stocks
Higher than 69% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Acadia Healthcare Co., Inc. has a market value of $2.8B and an enterprise value of $5.4B.
Revenue in the twelve months to 30 June 2026: $3.4B. The latest quarter shrank 0.4% year on year.
Net income over the same four quarters: −$1.1B, a −33.3% net margin.
Diluted earnings per share, trailing twelve months: $−12.45.
Free cash flow in the twelve months to 30 June 2026: −$134.0M, after $344.5M of capital spending.
Acadia Healthcare Co., Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 20.6×; forward P/E: 16.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Acadia Healthcare Co., Inc. employs 25,000 people — $135K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Acadia Healthcare Co., Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Acadia Healthcare reported quarterly earnings of $0.60 per share, above the Zacks Consensus Estimate of $0.46. Earnings were $0.72 per share in the year-earlier quarter.
Why it matters — ACHC watchers may note that quarterly earnings exceeded the consensus estimate, while remaining below the year-ago level.
Acadia Healthcare reported third-quarter 2026 revenue of $895.3 million, up 5.1% year over year. Same-facility revenue rose 5.2%, with patient days up 1.1% and revenue per patient day up 4.0%; the headline says the company raised full-year 2026 financial guidance.
Why it matters — The revenue growth and higher full-year guidance are updates on Acadia’s operating performance and outlook that ACHC watchers may wish to track.
Acadia Healthcare announced it will participate in two November 2026 investor conferences: the 2026 UBS Global Healthcare Conference on November 9 and the 2026 Stephens Annual Investment Conference on November 18. Its UBS presentation is scheduled to begin at 11:00 a.m. Eastern Time.
Why it matters — The appearances provide ACHC watchers with dates for upcoming opportunities to hear from the company at investor conferences.
The excerpt says GRAIL’s third-quarter earnings were expected to benefit from increased adoption of its Galleri test, expanding digital health partnerships, and growing clinical evidence of cancer detection.
Why it matters — The item concerns GRAIL rather than Acadia Healthcare, so it provides no direct information about ACHC.
A PRNewsWire item invites Acadia Healthcare shareholders to contact a firm to discuss their rights and options, at no cost or obligation. The firm says it would handle any matter on a contingent-fee basis.
Why it matters — The item raises a potential shareholder-rights issue involving ACHC insiders, which may be relevant to investors monitoring the company.
The 14 Wall Street analysts covering Acadia Healthcare Co., Inc. have a median 12-month price target of $33, with estimates ranging from $17 to $41. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Acadia Healthcare Co., Inc., 8 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Acadia Healthcare Co., Inc. 59 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Acadia Healthcare Co., Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +1.2% from the last close, and Ticker Nerd's factor model ranks Acadia Healthcare Co., Inc. 59 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Acadia Healthcare Co., Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $41 over the next 12 months.
Acadia Healthcare Co., Inc. returned +55.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Acadia Healthcare Company, Inc. is a behavioral healthcare services provider focused on delivering treatment across a range of clinical settings.
The most recent item we track (Zacks Investment Research, 5 Nov 2026): "Acadia Healthcare (ACHC) Surpasses Q3 Earnings and Revenue Estimates". Acadia Healthcare reported quarterly earnings of $0.60 per share, above the Zacks Consensus Estimate of $0.46. Earnings were $0.72 per share in the year-earlier quarter.
Acadia Healthcare Company, Inc. is a behavioral healthcare services provider focused on delivering treatment across a range of clinical settings. The company operates acute inpatient psychiatric facilities, specialty treatment centers, residential treatment programs, comprehensive treatment centers, and outpatient behavioral health services. Its offerings address mental health conditions, substance use disorders, and related recovery needs for patients and communities. Acadia Healthcare serves individuals through a network designed to provide both short-term stabilization and longer-term therapeutic care, making it an important participant in the U.S. behavioral health market. The company’s business is centered on facility-based care, coordinated treatment pathways, and access to specialized services across multiple levels of acuity. Founded in 2005 and headquartered in Franklin, Tennessee, Acadia Healthcare Company, Inc. remains a significant operator in the healthcare services sector.
CEO Ms. Debra K. Osteen · 25,000 employees · United States · https://www.acadiahealthcare.com
